Response assessment criteria for glioblastoma: Practical adaptation and implementation in clinical trials of antiangiogenic therapy

Current Neurology and Neuroscience Reports

Volumn 13, Issue 5, 2013, Pages

  Chinot, Olivier L ^a   Macdonald, David R ^b   Abrey, Lauren E ^c   Zahlmann, Gudrun ^c   Kerloëguen, Yannick ^c   Cloughesy, Timothy F ^d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiangiogenic therapy; Glioblastoma; Neurologic assessment; Radiologic assessment; Response assessment

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CEDIRANIB; IRINOTECAN; TEMOZOLOMIDE;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); GLIOBLASTOMA; HUMAN; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 84875175029     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0347-2     Document Type: Article

References (51)

1. CBTRUS. (2011) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf Accessed 24 January 2013.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuva (Pubitemid 40349501)
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359: 492-507.
4. Stupp R, Hegi ME, Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide vs radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-66.
5. Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep. 2011; 13: 50-6.
6. Reardon DA, Galanis E, DeGroot J.F., et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011; 13: 353-61.
7. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early vs delayed radiotherapy for low-grade astrocytoma and oligodenroglioma in adults: the EORTC 22845 randomized trial. Lancet. 2005; 366: 985-90. (Pubitemid 41323034)
8. Provenzale JM, Mancini MC. Assessment of intra-observer variability in measurement of high-grade brain tumors. J Neurooncol. 2012; 108: 477-83.
9. Levin VA, Crafts DC, Norman D.M., et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977; 47: 329-35. (Pubitemid 8170121)
10. Miller AB, Hoogstraten B, Staquet M., et al. Reporting results of cancer treatment. Cancer. 1981; 47: 207-14. (Pubitemid 11167383)
11. Macdonald DR, Cascino TL, Schold Jr SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-80. (Pubitemid 20195640)
12. Wen PY, Macdonald DR, Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963-72. Wen and colleagues set forth the RANO criteria as a means of updating the Macdonald Criteria for response assessment in gliomas. The authors reached a consensus to address recently characterized challenges in the evaluation of high grade gliomas, particularly with respect to pseudoprogression and pseudoresponse in the context of modern treatment regimens and technological advancements.
13. Therasse P, Arbuck SG, Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-16. (Pubitemid 30099779)
14. Eisenhauer EA, Therasse P, Bogaerts J., et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-47.
15. Galanis E, Buckner JC, Maurer M.J., et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol. 2006; 8: 156-65. (Pubitemid 46542660)
16. Shah GD, Kesari S, Xu R., et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006; 8: 38-46. (Pubitemid 43154449)
17. Gállego Pérez-Larraya J, Lahutte M, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol. 2012; 14: 667-73. This cohort study of 78 patients compared 4 different response assessment criteria (Macdonald, RECIST, RANO, and RECIST + F) and compared their ability to determine response and progression in patients treated with bevacizumab.
18. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. Am J Neuroradiol. 2008; 29: 419-24. (Pubitemid 351424049)
19. Sorensen AG, Batchelor TT, Wen P.Y., et al. Response criteria for glioma. Nat Clin Pract Oncol. 2008; 5: 634-44.
20. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol. 2011; 101: 319-23.
21. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumors. Nat Rev Neurosci. 2007; 8: 610-22.
22. Rubenstein JL, Kim J, Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000; 2: 306-14.
23. Kunkel P, Ulbricht U, Bohlen P., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001; 61: 6624-8. (Pubitemid 32896475)
24. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70: 779-87.
25. de Groot J.F., Fuller G, Kumar A.J., et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010; 12: 233-42.
26. Gerstner ER, Chen PJ, Wen P.Y., et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010; 12: 466-72.
27. Khayal IS, Polley MY, Jalbert L, et al. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol. 2010; 12: 908-16.
28. Keunen O, Johansson M, Oudin A., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011; 108: 3749-54.
29. de Groot J.F., Lamborn KR, Chang S.M., et al. Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol. 2011; 29: 2689-95.
30. Cairncross JG, Macdonald DR, Pexman J.H., et al. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology. 1988; 38: 724-6.
31. Watling CJ, Lee DH, Macdonald D.R., et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994; 12: 1886-9. (Pubitemid 24349391)
32. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11: 83-95. (Pubitemid 46075199)
33. Vredenburgh JJ, Desjardins A, Herndon II JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253-9. (Pubitemid 46424067)
34. van den Bent MJ, Vogelbaum MA, Wen P.Y., et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009; 27: 2905-8.
35. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009; 22: 633-8. This review article underlined the importance of pseudoprogression and pseudoresponse phenomena in patients with glioblastoma multiforme and their effect on radiographic assessment of response.
36. Hygino da Cruz Jr LC, Rodriguez I, Domingues RC Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol. 2011; 32: 1978-85.
37. Brandes AA, Franceschi E, Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26: 2192-7.
38. Pouleau HB, Sadeghi N, Balériaux D, et al. High levels of cellular proliferation predicts pseudoprogression in glioblastoma patients. Int J Oncol. 2012; 40: 923-8.
39. Chamberlain MC. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006; 67: 2089. (Pubitemid 44967404)
40. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008; 113: 405-10.
41. Pirzkall A, McGue C, Saraswathy S., et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2009; 11: 842-52.
42. Pope WB, Lai A, Nghiemphu P., et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006; 66: 1258-60. (Pubitemid 43739717)
43. Vredenburgh JJ, Desjardins A, Herndon II JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-9. (Pubitemid 350086473)
44. Friedman HS, Prados MD, Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-40.
45. Kreisl TN, Kim L, Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27: 740-5.
46. Chinot OL, de La Motte RT, Moore N, et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011; 28: 334-40.
47. Vogelbaum MA, Jost S, Aghi M.K., et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012; 70: 234-43.discussion 243-4
48. Polley MY, Lamborn KR, Chang S.M., et al. Six-month progression-free survival as an alternative primary efficacy end-point to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010; 12: 274-82.
49. Tombaugh TN, McIntyre NJ. The mini-mental state examination: A comprehensive review. J Am Geriatr Soc. 1992; 40: 922-35.
50. Minaya P, Baumstarck K, Berbis J., et al. The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. Eur J Cancer. 2012; 48: 904-11.
51. van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011; 12: 583-93.